Tag: Product approvals
Medicare evaluating coverage for $56,000 Alzheimer’s drug
WASHINGTON — Medicare on Monday launched a formal process to decide whether to cover Aduhelm, the new Alzheimer's drug whose $56,000-a-year price tag and...
FDA head calls for probe into Alzheimer’s drug review
WASHINGTON — The acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between some...
FDA trims use of contentious Alzheimer’s drug amid backlash
WASHINGTON — U.S. health regulators on Thursday approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer’s drug.
...
Does new Alzheimer’s drug work? Answers may miss 2030 target
WASHINGTON — When a controversial Alzheimer’s drug won U.S. approval, surprise over the decision quickly turned to shock at how long it might take...
Putin reveals he was vaccinated with Russia’s Sputnik V
MOSCOW — President Vladimir Putin revealed Wednesday that he had received the domestically developed Sputnik V vaccine earlier this year, stressing the importance of...
Alzheimer’s drug stirs hope for patients, worry for doctors
In the weeks since a new Alzheimer's drug was approved, hopeful patients have bombarded Dr. Alireza Atri with calls and emails about a treatment...
Lilly to seek FDA approval for potential Alzheimer’s drug
INDIANAPOLIS — Eli Lilly said Thursday that it will submit its potential Alzheimer’s treatment to federal regulators later this year.
...
US officials extend expiration dates on J&J vaccine doses
WASHINGTON — Johnson & Johnson said Thursday that U.S. regulators extended the expiration date on millions of doses of its COVID-19 vaccine by an...
Germany: Delay for CureVac shot won’t hurt vaccine campaign
BERLIN — Germany's health ministry on Wednesday downplayed the possible impact on the country's coronavirus vaccine campaign after reports that the shot being developed...
EXPLAINER: How will insurers cover a new Alzheimer’s drug?
Federal regulators have approved the first new drug for Alzheimer’s disease in nearly 20 years, leaving patients waiting to see how insurers will handle...